Literature DB >> 18416462

Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro.

Su-Gang Shen1, Dong Zhang, Heng-Tong Hu, Jun-Hui Li, Zheng Wang, Qing-Yong Ma.   

Abstract

AIM: To discuss the expression of alpha-adrenoreceptors in pancreatic cancer cell lines PC-2 and PC-3 and the effects of alpha1- and alpha2-adrenoreceptor antagonists, yohimbine and urapidil hydrochloride, on the cell lines in vitro.
METHODS: We cultured the human ductal pancreatic adenocarcinoma cell lines PC-2 and PC-3 and analyzed the mRNA expression of alpha1- and alpha2-adrenergic receptors by reverse transcription polymerase chain reaction (RT-PCR). The effects of yohimbine and urapidil hydrochloride on cell proliferation were assessed by 3-(4,5-dimethylthiasol-2-yl)-2,4,-diphenyltetrazolium bromide (MTT) assay. Apoptosis was detected using the terminal deoxyribonucleotidyl transferase (TdT)-mediated biotin-16-dUTP nick-end labeling (TUNEL) assay and flow cytometry (FCM).
RESULTS: PC-2 expressed mRNA in alpha1- and alpha2-adrenoreceptors. MTT assays showed that urapidil hydrochloride had no effect on PC-3 cell lines. However, exposure to urapidil hydrochloride increased DNA synthesis in PC-2 cell lines as compared to the control group. PC-2 cell lines were sensitive to both drugs. The proliferation of the 2 cell lines was inhibited by yohimbine. Cell proliferation was inhibited by yohimbine via apoptosis induction.
CONCLUSION: The expression of alpha1- and alpha2-adrenoreceptors is different in PC-2 and PC-3 cell lines, which might be indicative of their different functions. The alpha2-adrenoceptor antagonist, yohimbine, can inhibit the proliferation of both cell lines and induce their apoptosis, suggesting that yohimbine can be used as an anticancer drug for apoptosis of PC-2 and PC-3 cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18416462      PMCID: PMC2705090          DOI: 10.3748/wjg.14.2358

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

Review 1.  Mechanisms of smoking-related lung and pancreatic adenocarcinoma development.

Authors:  Hildegard M Schuller
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

2.  Identification of functional beta-adrenoceptors in Caco-2 cell membranes.

Authors:  R Odore; P Badino; A L Stammati; I De Angelis; F Zucco; C Belloli; G Re
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

3.  Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell.

Authors:  G R Badino; A Novelli; C Girardi; F Di Carlo
Journal:  Pharmacol Res       Date:  1996 Apr-May       Impact factor: 7.658

4.  Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas.

Authors:  D L Weddle; P Tithoff; M Williams; H M Schuller
Journal:  Carcinogenesis       Date:  2001-03       Impact factor: 4.944

Review 5.  Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies.

Authors:  Murielle Mimeault; Randall E Brand; Aaron A Sasson; Surinder K Batra
Journal:  Pancreas       Date:  2005-11       Impact factor: 3.327

Review 6.  Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.

Authors:  Natasha Kyprianou
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

7.  The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid.

Authors:  H M Schuller; P K Tithof; M Williams; H Plummer
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

8.  Alpha2-adrenergic effect on human breast cancer MCF-7 cells.

Authors:  S M Vázquez; O Pignataro; I A Luthy
Journal:  Breast Cancer Res Treat       Date:  1999-05       Impact factor: 4.872

9.  Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.

Authors:  N Kyprianou; C M Benning
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

10.  Evaluation of beta-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP.

Authors:  Rangaswamy Nagmani; David S Pasco; Ruben D Salas; Dennis R Feller
Journal:  Biochem Pharmacol       Date:  2003-05-01       Impact factor: 5.858

View more
  14 in total

Review 1.  β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives.

Authors:  Marisa Coelho; Cátia Soares-Silva; Daniela Brandão; Franca Marino; Marco Cosentino; Laura Ribeiro
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-05       Impact factor: 4.553

2.  Anticancer potential of yohimbine in drug-resistant oral cancer KB-ChR-8-5 cells.

Authors:  Nasimudeen R Jabir; Mohd Shahnawaz Khan; Nouf Omar Alafaleq; Huma Naz; Bakrudeen Ali Ahmed
Journal:  Mol Biol Rep       Date:  2022-08-16       Impact factor: 2.742

3.  Identification of potential inhibitory analogs of metastasis tumor antigens (MTAs) using bioactive compounds: revealing therapeutic option to prevent malignancy.

Authors:  Anik Banik; Sheikh Rashel Ahmed; Emran Hossain Sajib; Anamika Deb; Shiuly Sinha; Kazi Faizul Azim
Journal:  Mol Divers       Date:  2021-11-07       Impact factor: 3.364

4.  α2A-Adrenergic Receptor Inhibits the Progression of Cervical Cancer Through Blocking PI3K/AKT/mTOR Pathway.

Authors:  Weina Wang; Xin Guo; Huiwen Dan
Journal:  Onco Targets Ther       Date:  2020-10-15       Impact factor: 4.147

5.  Maternal obesity programmes offspring development of non-alcoholic fatty pancreas disease.

Authors:  Jude A Oben; Trusha Patel; Angelina Mouralidarane; Ann Maj Samuelsson; Phillippa Matthews; Joaquim Pombo; Maelle Morgan; Chad McKee; Junpei Soeda; Marco Novelli; Lucilla Poston; Paul Taylor
Journal:  Biochem Biophys Res Commun       Date:  2010-02-17       Impact factor: 3.575

6.  HIF-1alpha links beta-adrenoceptor agonists and pancreatic cancer cells under normoxic condition.

Authors:  Heng-tong Hu; Qing-yong Ma; Dong Zhang; Su-gang Shen; Liang Han; Ya-dong Ma; Ruo-fei Li; Ke-ping Xie
Journal:  Acta Pharmacol Sin       Date:  2009-12-28       Impact factor: 6.150

7.  Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cells.

Authors:  Liancai Wang; Han Liu; Xiangli Chen; Min Zhang; Keping Xie; Qingyong Ma
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

8.  Effect of 5-HT7 receptor blockade on liver regeneration after 60-70% partial hepatectomy.

Authors:  Konstantinos N Tzirogiannis; Kalliopi T Kourentzi; Sofia Zyga; Vassiliki Papalimneou; Maria Tsironi; Agni D Grypioti; Ioannis Protopsaltis; Dimitrios Panidis; Georgios I Panoutsopoulos
Journal:  BMC Gastroenterol       Date:  2014-11-30       Impact factor: 3.067

Review 9.  The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.

Authors:  Mallory Batty; Rachel Pugh; Ilampirai Rathinam; Joshua Simmonds; Edwin Walker; Amanda Forbes; Shailendra Anoopkumar-Dukie; Catherine M McDermott; Briohny Spencer; David Christie; Russ Chess-Williams
Journal:  Int J Mol Sci       Date:  2016-08-16       Impact factor: 5.923

10.  A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening.

Authors:  Jouhyun Jeon; Satra Nim; Joan Teyra; Alessandro Datti; Jeffrey L Wrana; Sachdev S Sidhu; Jason Moffat; Philip M Kim
Journal:  Genome Med       Date:  2014-07-30       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.